Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular CarcinomaMakoto Chuma, Shin Maeda, Hiroyuki Fukuda et al.|Cancers|2020Cited by 54
Circulating microRNA‐1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinomaMakoto Chuma, Naoya Sakamoto, Hidenori Toyoda et al.|Hepatology Research|2019Cited by 43
Contrast-enhanced ultrasonography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinomaKazushi Numata, Katsuaki Tanaka, Hiroyuki Fukuda et al.|European Journal of Radiology|2013Cited by 38
Use of vessel patterns on contrast-enhanced ultrasonography using a perflubutane-based contrast agent for the differential diagnosis of regenerative nodules from early hepatocellular carcinoma or high-grade dysplastic nodules in patients with chronic liver diseaseKazushi Numata, Katsuaki Tanaka, Hiroyuki Fukuda et al.|Abdominal Imaging|2015Cited by 36
Rate of local tumor progression following radiofrequency ablation of pathologically early hepatocellular carcinomaYoshiteru Hao, Katsuaki Tanaka, Kazushi Numata et al.|World Journal of Gastroenterology|2017Cited by 29